Ticker: CAH

Cardinal Health

Healthcare Healthcare Medical - Distribution

Price 236.02

Reco Buy Potential 61 Risk 57 Updated 2026-09-09

Official website

Forecast impact

positive

Target +14.6% target fill 87.3%

Reaction D5 +1.69% · D10 -0.42% fresh confirmed

Impact Potential +3 · Risk -1 valid until 2026-09-12

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Cardinal Health is a global healthcare services and products company. It operates in two main segments: Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceuticals, while the Medical segment provides medical and surgical products. Major revenue sources include pharmaceutical distribution, medical product sales, and supply chain services.

Investment Profile

The investment profile of Cardinal Health is more aligned with balanced investors, given its stable revenue growth and moderate dividend yield. The company demonstrates potential for steady returns while maintaining a manageable risk level. This profile may appeal to those seeking a combination of growth and income.

Category: Healthcare Sector: Healthcare Industry: Medical - Distribution Investment style: Balanced Horizon: Medium-term Company type: Blue Chip Company type: Large Cap

Fundamental metrics (experimental) Updated: 2026-09-10

EPS (TTM) — earnings per share for the last 12 months, $: 6.56
Revenue QoQ — quarter-over-quarter revenue growth: -6.9%
EPS surprise: 12.4%
20d volatility: 1.4%
Dividend yield: 1.2%
last ex-date: 2026-04-01

AI recommendation changes

Date	Before	After	Reason
2026-09-08	Hold	Buy	Mixed signals; monitor for improved fundamentals.
2026-08-31	Buy	Hold	Mixed performance; cautious outlook amid revenue decline.
2026-08-22	Hold	Buy	Mixed performance; cautious outlook amid revenue decline.
2026-08-14	Buy	Hold	Weak fundamentals and mixed momentum signal caution.
2026-07-28	Hold	Buy	Mixed performance; cautious due to revenue decline.
2026-07-09	Buy	Hold	Mixed performance; cautious outlook amid revenue decline.
2026-06-27	Hold	Buy	Strong momentum but revenue decline raises concerns.
2026-06-19	Buy	Hold	Weak revenue growth raises concerns despite positive EPS surprise.
2026-06-05	Hold	Buy	Solid fundamentals, but mixed momentum signals present uncertainty.
2026-05-24	Buy	Hold	Mixed performance; cautious outlook amid market pressures.
2026-05-16	Hold	Buy	Mixed momentum; fundamentals show moderate strength.
2026-05-08	—	Hold	Weak momentum and high risk overshadow fundamentals.
2026-05-08	Hold	Hold	Компания показывает отрицательную динамику цен на акции за последние месяцы, однако имеет стабильный EPS и небольшой рост выручки. Рекомендуется удерживать акции до прояснения ситуации на рынке.
2026-04-25	Buy	Hold	Компания показывает умеренный рост выручки и положительный сюрприз по EPS, однако недавние падения цены акций и негативные тренды на коротких сроках вызывают опасения.
2026-01-30	Hold	Buy	Компания показывает сильный рост за последние 120 дней, что свидетельствует о положительной динамике. Умеренный риск связан с отсутствием данных по EPS и доходам, но общий тренд выглядит многообещающе.
2026-01-29	Buy	Hold	Компания показывает стабильный рост за последние 120 дней, однако отсутствие данных по EPS и доходам вызывает некоторые опасения. Рекомендуется удерживать акции до получения более ясной финансовой информации.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-08-19	RBC Capital	Update	— → 276	234.98
2026-08-13	Barclays	Target Raised	258 → 275	234.16
2026-08-12	Morgan Stanley	Target Raised	255 → 265	236.635
2026-08-12	Evercore ISI	Target Raised	265 → 270	240.26
2026-08-12	UBS	Target Raised	274 → 280	240.26
2026-08-12	Wells Fargo	Target Raised	245 → 277	240.26
2026-08-12	Mizuho Securities	Target Raised	— → 250	240.26
2026-08-12	Robert W. Baird	Target Raised	251 → 274	240.26
2026-08-11	Leerink Partners	Target Raised	275 → 292	240.26
2026-07-20	UBS	Target Raised	260 → 274	226.42
2026-05-01	Robert W. Baird	Target Lowered	257 → 248	195.08
2026-04-08	Evercore ISI	Target Lowered	260 → 240	215.13
2026-03-09	Leerink Partners	Update	— → 275	222.28
2026-02-24	Barclays	Target Raised	243 → 258	224.82
2026-02-10	Wells Fargo	Target Raised	237 → 256	225.76
2026-02-06	Morgan Stanley	Target Raised	245 → 255	229.63
2026-02-06	Robert W. Baird	Target Raised	250 → 252	228.7841
2026-02-06	UBS	Target Raised	250 → 260	228.63
2026-02-06	Mizuho Securities	Target Raised	222 → 235	227.18
2026-02-05	Evercore ISI	Target Raised	— → 260	227.18
2026-01-29	Morgan Stanley	Target Raised	224 → 245	210.39

News Page 1 of 1

Analysts raised Cardinal Health (CAH) target price following strong profit guidance despite revenue miss

08/11/2026, 01:37 PM business rating_growth Analysts: analysts healthcare Cardinal Health

Cardinal Health's strong earnings guidance and profitability improvements, despite a revenue miss, highlight its potential for growth, prompting analysts to raise their price target for the stock.

Stocks to Watch: Riot Platforms Surges on Strong Revenue, Hims & Hers Health Lowers EBITDA Outlook, Intel Upsizes Stock Offering

08/11/2026, 04:36 AM business review Hims & Hers Health Plug Power Cardinal Health RIOT Intel First Solar

Several companies are experiencing significant stock movements in premarket trading, with notable impacts from earnings reports and stock offerings that could influence investor sentiment.

Boeing Sells Noncore Subsidiaries to Archer Aviation, Strengthening Focus on Core Operations

08/10/2026, 09:39 AM business announcement aero_defense Boeing Archer Aviation (ACHR) Cardinal Health Intel

Investors are reacting to mixed stock performance amid geopolitical tensions and upcoming economic data, while notable corporate developments include Intel's stock sale and Boeing's strategic divestiture to Archer Aviation.

Cardinal Health (CAH) Expands Home Care Segment with $360 Million Acquisitions of AdaptHealth’s Diabetes Unit and Strive Medical

07/21/2026, 10:37 AM business announcement healthcare Cardinal Health

Cardinal Health's recent acquisitions of AdaptHealth's diabetes health business and Strive Medical for $360 million highlight the company's strategy to enhance its home care segment, which is experiencing rapid growth and higher margins compared to its traditional distribution operations.

Analysts see 35% upside for Honeywell Aerospace (HONA) as Jim Cramer highlights undervaluation

06/30/2026, 09:37 AM business forecast Analysts: analysts aero_defense Micron Honeywell Cardinal Health Eli Lilly

Investors are encouraged by a strong stock market performance and specific opportunities in semiconductor and aerospace sectors, particularly with companies like Micron and Honeywell Aerospace showing potential for significant growth.

Cramer Highlights Buying Opportunity in AI Stocks Amid Market Cooling

06/05/2026, 10:33 AM economy review ai tech CrowdStrike Holdings SpaceX Cardinal Health Intel Johnson & Johnson Apple Broadcom Eli Lilly

The recent decline in stock prices, particularly in the tech sector, presents a potential buying opportunity for investors, especially in chip stocks and AI-related companies, according to Jim Cramer.